Enhanced dissolution and systemic availability of albendazole formulated as solid dispersions

Pharmaceutical Development and Technology

Volumn 18, Issue 2, 2013, Pages 434-442

  Castro, Silvina G ^a,b   Sanchez Bruni, Sergio F ^b,c   Urbizu, Lucía P ^b,c   Confalonieri, Alejandra ^b,c   Ceballos, Laura ^b,c   Lanusse, Carlos E ^b,c   Allemandi, Daniel A ^a,b   Palma, Santiago D ^a,b  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b Consejo Nacional de Investigaciones Científicas y Técnicas CONICET ^*  (Argentina)

^c Facultad de Ciencias Veterinarias   (Argentina)

Author keywords

Albendazole; Mice; Pharmacokinetic; Poloxamer; Solid dispersions

Indexed keywords

ALBENDAZOLE; MACROGOL 6000; POLOXAMER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; HYDROPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALBENDAZOLE; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; MALE; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; SOLUBILITY; SUSPENSIONS;

EID: 84872442955     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.693509     Document Type: Article

References (32)

1. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60 (Pubitemid 30326688)
2. Amidon GL, Lennernas H, Shah VP, Crison Jr. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-420
3. Bley H, Fussnegger B, Bodmeier R. Characterization and stability of solid dispersions based on PEG/polymer blends. Int J Pharm 2010;390:165-173
4. Wang X, de Armas HN, Blaton N, Michoel A, Van den Mooter G. Phase characterization of indomethacin in binary solid dispersions with PVP VA64 or Myrj 52. Int J Pharm 2007;345:95-100 (Pubitemid 350087545)
5. Sethia S, Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm 2004;272:1-10 (Pubitemid 38293005)
6. Sekiguchi K, Obi N, Ueda Y. Studies on absorption of eutectic mixture. Ii. Absorption of fused conglomerates of chloramphenicol and urea in rabbits. Chem Pharm Bull 1964;12:134-144
7. Levy G. Effect of particle size on dissolution and gastrointestinal absorption rates of pharmaceuticals. Am J Pharm Sci Support Public Health 1963;135:78-92
8. Kanig JL. Properties of fused mannitol in compressed tablets. J Pharm Sci 1964;53:188-192
9. Janssens S, de Armas HN, D'Autry W, Van Schepdael A, Van den Mooter G. Characterization of ternary solid dispersions of Itraconazole in polyethylene glycol 6000/polyvidone-vinylacetate 64 blends. Eur J Pharm Biopharm 2008;69:1114-1120
10. Wang X, Michoel A, Van den Mooter G. Study of the phase behavior of polyethylene glycol 6000-itraconazole solid dispersions using DSC. Int J Pharm 2004;272:181-187 (Pubitemid 38293023)
11. Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 2008;70:493-499
12. Marin MT, Margarit MV, Salcedo GE. Characterization and solubility study of solid dispersions of flunarizine and polyvinylpyrrolidone. Farmaco 2002;57:723-727 (Pubitemid 35287006)
13. Castro SG, Sanchez Bruni S, Lanusse CE, Allemandi DA, Palma SD. Improved Albendazole Dissolution Rate in Pluronic 188 Solid Dispersions. AAPS Pharm Sci Tech. Doi: 10.1208/s12249-010- 9517-6. 2010
14. Kalaiselvan R, Mohanta GP, Manna PK, Manavalan R. Studies on mechanism of enhanced dissolution of albendazole solid dispersions with crystalline Carriers. Indian Journal of Pharmaceutical Sciences 2006; 68:599-607 (Pubitemid 46087768)
15. Collett JH. Poloxamer. In: Rowe RC, Sheskey PJ, Quinn ME editors. Handbook of pharmaceutical excipients ed. 6th edition, London, Chicago:Pharmaceutical Press 2009; 506-509
16. Zhai H, Li S, Andrews G, Jones D, Bella S, Walker G. Nucleation and growth in fluidised hot melt granulation. Powder Technol 2009;189:230-237
17. Vilhelmsen T, Eliasen H, Schaefer T. Effect of a melt agglomeration process on agglomerates containing solid dispersions. Int J Pharm 2005;303:132-142 (Pubitemid 41318030)
18. Wallik D. Polyethylene Glycol, In: Rowe RC, Sheskey PJ, Quinn ME editors. Handbook of pharmaceutical excipients. ed. 6th edition, London, Chicago:Pharmaceutical Press 2009; 517-522
19. Fawaz F, Bonini F, Guyot M, Bildet J, Maury M, Lagueny AM. Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion complexes in rabbits. International Journal of Pharmaceutics 1996; 132:271-275 (Pubitemid 26158727)
20. Damian F, Blaton N, Kinget R, Van den Mooter G. Physical stability of solid dispersions of the antiviral agent UC-781 with PEG 6000, Gelucire 44/14 and PVP K30. Int J Pharm 2002;244:87-98
21. Wang X, Michoel A, Van den Mooter G. Study of the phase behavior of polyethylene glycol 6000-itraconazole solid dispersions using DSC. International Journal of Pharmaceutics. 2004; 272:181-187
22. Cook GC. Use of benzimidazole chemotherapy in human helminthiases: Indications and efficacy. Parasitol Today (Regul Ed) 1990;6:133-136
23. Townsend LB, Wise DS. The synthesis and chemistry of certain anthelmintic benzimidazoles. Parasitol Today (Regul Ed) 1990;6:107-112
24. Sanchez Bruni SF, Jones DG, McKellar QA. Pharmacological approaches towards rationalizing the use of endoparasitic drugs in small animals. J Vet Pharmacol Ther 2006;29:443-457 (Pubitemid 44684087)
25. Jung H, Medina L, Garcia L, Fuentes I, Moreno-Esparza R. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J Pharm Pharmacol 1998;50:43-48 (Pubitemid 28052519)
26. Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Gordo F, Torrado JJ. The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharm 2004;272:29-36 (Pubitemid 38293008)
27. Vogt M, Kunath K, Dressman JB. Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. Eur J Pharm Biopharm 2008;68:330-337
28. Notari RE. Pharmacokinetics. Biopharmaceutics and Clinical Pharmacokinetics, In: Notari RE, editor, 4th edition, New York, NY, USA: Marcel Dekker Inc, 1987; 45-128
29. Gibaldi M, Perrier D. Pharmacokinetics. In: Editor. New York, USA:Marcel, Dekker. 2nd edition. 1982;45-109
30. Sanchez S, Sallovitz J, Savio E, Mckellar Q, Lanusse C. Comparative availability of two oral dosage forms of albendazole in dogs. Vet J 2000;160:153-156
31. Jung H, Medina L, Garcia L, Fuentes I, Moreno-Esparza R. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J Pharm Pharmacol. 1998; 50:43-48 (Pubitemid 28052519)
32. Evrard B, Chiap P, DeTullio P, Ghalmi F, Piel G, Van Hees T et al. Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyclodextrin. J Control Release 2002;85:45-50 (Pubitemid 35449452)